5De Knegt RJ,Bezemer G,Van Gool AR,et al. Randomised clinicaltrial:escitalopram for the prevention of psychiatric adverse eventsduring treatment with peginterferon-alfa-2a and ribavirin forchronic hepatitis C [J].Aliment Pharmacol Ther,2011,34(11-12):1306-17.
6McCaughan GW,Omata M,Amarapurkar D,et al. Asian PacificAssociation for the Study of the Liver consensus statements on thediagnosis,management and treatment of hepatitis C virus infection[J].J Gastroenterol Hepatol,2007,22(5):615-33.
7Manns MP,McHutchison JG,Gordon SC,et al. Peginterferonalfa-2b plus ribavirin compared with interferon alfa-2b plusribavirin for initial treatment of chronic hepatitis C:a randomisedtrial[J].Lancet,2001,358(9286):958-65.
8Hadziyannis SJ,Sette H Jr,Morgan TR,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C:arandomized study of treatment duration and ribavirin dose[J].AnnIntern Med,2004,140(5):346-55.
9Lieb K,Engelbrecht MA,Gut 0,et al. Cognitive impairment inpatients with chronic hepatitis treated with interferon alpha(IFNalpha):results from a prospective study [J].Eur Psychiatry.2006,21(3):204-10.
10Jakiche A,Paredez EC,Tannan PK,et al. Trend of depression andthe use of psychiatric medications in U.S. Veterans with hepatitis Cduring interferon-based therapy [J].Am J Gastroenterol,2007,102(11):2426-33.
